Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.65 |
| ▸ | CTSS | P25774 | 6/20 | 0.57 |
| ▸ | CTSK | P43235 | 5/20 | 0.57 |
| ▸ | CTSB | P07858 | 4/20 | 0.57 |
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907894 | 1.00 | ACE (0.65) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL268723 | 1.00 | ACE (0.65) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL16423 | 1.00 | ACE (0.65) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL3704551 | 0.88 | ACE (0.60) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL3704550 | 0.88 | ACE (0.60) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL5529843 | 0.88 | REN (0.61) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL21409100 | 0.88 | CTSK (0.57) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL8241449 | 0.88 | CTSK (0.57) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL12305798 | 0.88 | CTSK (0.57) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL3731261 | 0.87 | CTSS (0.73) | ACECTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104910046-B | Phenylacetylene derivative with double chiral carbon atoms on pendant group and preparation method and application thereof | 哈尔滨工程大学 | 2017-05-24 | — | — | CN | claimed |
| CN-104910039-A | Functional phenylacetylene compound and preparation method thereof | UNIV HARBIN ENG | 2015-09-16 | — | — | CN | claimed |
| US-20240057599-A1 | METHODS FOR IMPROVING FRUIT QUALITY | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2024-02-22 | — | — | US | disclosed |
| US-11812746-B2 | Method of controlling fungal infections in plants | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2023-11-14 | — | — | US | disclosed |
| WO-2023102140-A1 | TMPRSS2 INHIBITORS AND METHODS OF USE | TOPSPIN THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20200383327-A1 | METHOD OF IMPROVING PLANT PERFORMANCE | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2020-12-10 | — | — | US | disclosed |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190246639-A1 | METHOD OF CONTROLLING FUNGAL INFECTIONS IN PLANTS | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCHORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2019-08-15 | — | — | US | disclosed |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | Venenum Biodesign, LLC (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2017214359-A1 | NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS | VENENUM BIODESIGN LLC (US) | 2017-12-14 | — | — | WO | disclosed |
| CN-104910046-B | Phenylacetylene derivative with double chiral carbon atoms on pendant group and preparation method and application thereof | 哈尔滨工程大学 | 2017-05-24 | — | — | CN | disclosed |
| US-8133907-B2 | Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin | ELI LILLY AND COMPANY (US) | 2012-03-13 | — | — | US | disclosed |
| WO-2012004678-A2 | SERINE PROTEASE INHIBITORS | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| EP-1912946-B1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | LILLY CO ELI (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080214616-A1 | Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
| EP-1912946-A1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | Eli Lilly and Company (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| WO-2007015767-A1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | ACE 128/4885CTSS 1105/4885CTSK 2645/4885 |
| US-20080214616-A1 | Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors | DPP4, DPP3, DPP7 | ACE 135/4885CTSS 1680/4885CTSK 2589/4885 |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | GABRA5, GABRA1, GABRA4 | ACE 4424/4885CTSS 2857/4885CTSK 2898/4885 |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | GABRA5, GABRA1, GABBR2 | ACE 3988/4885CTSS 2520/4885CTSK 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.